Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2010

View Archived Issues

Scientists shed light on protective role of DJ-1 in Parkinson's disease and isradipine potential

ACT-178882/MK-1597 shows suitable profile for development for hypertension

Chimerix's CMX-157 is safe in first-in-human study in healthy volunteers

Novartis submits MAA to EMA for multi-component meningococcal b vaccine Bexsero

TetraLogic Pharmaceuticals claims new inhibitors of apoptosis protein inhibitors

Corcept presents phase III data for Corlux for Cushing's syndrome

Bayer Schering Pharma claims novel antagonists of proteinase-activated receptor 1

Astellas Pharma patents new inhibitors of protein kinase C theta

Cylene Pharmaceuticals divulges novel inhibitors of protein kinases

Cyclacel's cell cycle inhibitor CYC-065 suppresses growth of MM cell in vitro

HDAC inhibitor PCI-24781 displays in vivo anti-inflammatory effects

Arena and Eisai attend end-of-review meeting with FDA for lorcaserin

FDA warns about abnormal heart rhythms associated with dolasetron mesylate

Phase IIb study begins of Azixa as front-line treatment for glioblastoma multiforme

Dynavax reports data from phase Ib study of hepatitis B therapeutic vaccine DV-601

Alimera Sciences receives FDA complete response for Iluvien

New orexin receptor OX2 antagonists described by Merck & Co.

Novartis receives E.U. approval for Tasigna in newly diagnosed Ph+ CML

Teva receives FDA complete response letter for lower-volume glatiramer acetate

DSM to add to nutrition segment through acquisition of Martek

Enrollment completed in phase II study of belinostat in carcinoma of unknown primary

BioCrossroads provides support to Aarden for TB program

Oramed receives grant to support its diabetes research

Stem Cell Therapeutics meets with FDA for NTx-265 program

Meda obtains rights to market EpiPen auto-injector in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.